Grant of Options
CRISM Therapeutics Corporation announced on June 30, 2026, the grant of options under its EMI Share Option Plan to directors Andrew Webb, Chris McConville, and Gerry Beaney. Andrew Webb received options for 504,000 ordinary shares at an exercise price of 10p, Chris McConville for 408,798 shares at 10p, and Gerry Beaney for 99,999 shares at 10p. These options will vest over two years, with one-third vesting on grant, one-third on the first anniversary, and one-third on the second anniversary, becoming exercisable on the second anniversary and expiring in June 2036.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has granted options over ordinary shares of no par value ('Ordinary Shares') in the Company (the 'Options') on 30 June 2026 to certain directors as set out below.
| Director | Total number of Ordinary Shares subject to option grant | Options exercise price | Vesting Period |
|---|---|---|---|
| Andrew Webb | 504,000 | 10p | 30 June 2026 - 30 June 2028 |
| Chris McConville | 408,798 | 10p | 30 June 2026 - 30 June 2028 |
| Gerry Beaney | 99,999 | 10p | 30 June 2026 - 30 June 2028 |
The awards have been made under the Company's existing EMI Share Option Plan. The Options will vest as to one-third on grant, one-third on the first anniversary of grant and one-third on the second anniversary of grant. The options will become exercisable on the second anniversary of grant and expire on 30 June 2036, being 10 years from the date of grant.
The grant of Options to the Executive directors was overseen by the Remuneration Committee which made recommendations to the Board based on its assessment of each executive's personal performance during 2025 and 2026.
The Company's LEI is 213800XFW6MKVCHHPW88.
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | 1) Andrew Webb 2) Gerald Beaney 3) Chris McConville |
| 2 | Reason for the notification | |
| a) | Position/status | 1) Executive Chairman 2) Non-Executive Director 3) Chief Scientific Officer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | CRISM Therapeutics Corporation |
| b) | LEI | 213800XFW6MKVCHHPW88 |
| a) | Description of the financial instrument, type of instrument | Ordinary shares with no par value |
| Identification code | ISIN: VGG042401262 | |
| b) | Nature of the transaction | Grant of Options |
| c) | Price(s) and volume(s) | Director/PDMR Exercise Price Volume Andrew Webb £0.10 504,000 Gerald Beaney £0.10 99,999 Chris McConville £0.10 408,798 |
| d) | Aggregated information | |
| - Aggregated volume | N/A | |
| - Price | N/A | |
| e) | Date of the transaction | 30 June 2026 |
| f) | Place of the transaction | Outside a trading venue |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.